CeriBell (NASDAQ:CBLL) Shares Gap Up - What's Next?

Shares of CeriBell (NASDAQ:CBLL - Get Free Report) gapped up prior to trading on Monday . The stock had previously closed at $21.03, but opened at $22.09. CeriBell shares last traded at $21.27, with a volume of 7,158 shares.

Analysts Set New Price Targets

Several analysts recently weighed in on CBLL shares. TD Cowen lifted their target price on shares of CeriBell from $31.00 to $36.00 and gave the company a "buy" rating in a report on Monday, December 9th. Canaccord Genuity Group reaffirmed a "buy" rating and issued a $33.00 price objective on shares of CeriBell in a research note on Wednesday, February 26th. Six analysts have rated the stock with a buy rating, According to MarketBeat.com, CeriBell presently has an average rating of "Buy" and an average price target of $32.60.

CeriBell Trading Up 0.7 %

The business has a fifty day moving average of $22.36.

CeriBell (NASDAQ:CBLL - Get Free Report) last released its earnings results on Tuesday, February 25th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.32) by ($0.08). The company had revenue of $18.53 million during the quarter, compared to analysts' expectations of $17.55 million. On average, research analysts expect that CeriBell will post -2.46 EPS for the current year.

Remove Ads

Hedge Funds Weigh In On CeriBell

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. FMR LLC purchased a new position in CeriBell in the fourth quarter worth approximately $128,120,000. TPG GP A LLC acquired a new stake in shares of CeriBell in the 4th quarter valued at $102,677,000. Red Tree Management LLC purchased a new stake in shares of CeriBell during the 4th quarter worth $57,083,000. Yu Fan acquired a new position in shares of CeriBell during the fourth quarter worth $31,631,000. Finally, ABG WTT Global Life Science Capital Partners GP Ltd purchased a new position in CeriBell in the fourth quarter valued at $28,160,000.

CeriBell Company Profile

We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.